OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs
WALTHAM, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to potentially predict patient responses to its first-in-class targeted oncology therapies, today announced the appointment of Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs.
“I am thrilled to reunite with Colleen and have her join our team given her deep expertise in oncology drug development,” said Laura Benjamin, Ph.D., President and Chief Executive Officer at OncXerna Therapeutics. “Her track record of success in developing and executing clinical development and regulatory strategies is impressive. This track record will be critical as we prepare to advance our navicixizumab and bavituximab programs towards registration trials using our unique RNA-base